| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein,...
 
																	- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributo...
 
																	Biomerica (NASDAQ:BMRA) reported $1.380 million in sales this quarter. This is a 23.63 percent decrease over sales of $1.807 mi...
 
																	New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFo...
 
																	 
																	.
 
																	
 
																	10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH....